# US 2008/0269129 A1 · Polypeptide and dna thereof useful as a neovascular marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269129 A1
- Document ID: US20080269129A1
- Status: Published application
- Kind: A1
- Application number: 12/027,873
- Filed: 2008-02-07
- Published: 2008-10-30
- Earliest claimed: 2001-05-07
- Assignees: Yasufumi Sato; Shionogi & Co., Ltd.
- Inventors: Yasufumi SATO; Hikaru Sonoda; Hideki Ohta
- Web page: https://patentgrep.com/patent/US20080269129A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2799/026: where the vector is derived from a baculovirus
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method for diagnosis of ovarian cancer or colon cancer comprising detecting hybridization of a polynucleotide comprising the complement of the nucleotide sequence of SEQ ID NO: 1, or a fragment of at least 15 consecutive nucleotides thereof, to an RNA of 6 kb, hybridization at a level of about 2-fold greater than normal indicating a diagnosis of ovarian cancer or colon cancer.

### Claim 29 (depends on 28)

The method of claim 28, wherein hybridization to a polynucleotide consisting of a fragment from nucleotides 1-1480 of SEQ ID NO: 1, or to a fragment of at least 15 consecutive nucleotides thereof, is detected.

### Claim 30 (depends on 28)

The method of claim 28, wherein hybridization to a polynucleotide consisting of a fragment from nucleotides 386-1480 of SEQ ID NO: 1, or to a fragment of at least 15 consecutive nucleotides thereof, is detected.

### Claim 31 (depends on 28)

The method of claim 28, wherein the hybridization is performed under conditions of 0.5M phosphoric acid, 1% cattle serum albumin, 1 mM EDTA and 7% sodium dodecyl sulfate at 65° C.

### Claim 32

A method for inhibiting proliferation of vascular endothelial cells comprising administering a composition comprising the polypeptide KIAA 1036 to said vascular endothelial cells or expressing a polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 in said vascular endothelial cells.

### Claim 33 (depends on 31)

The method of claim 31, in which the composition is administered to a subject or said polynucleotide is expressed in a subject.

### Claim 34 (depends on 31)

The method of claim 31, in which the composition is administered to cells in culture or said polynucleotide is expressed in cells in culture.

### Claim 35 (depends on 33)

The method of claim 33, in which the subject presents with colon cancer or ovarian cancer.

### Claim 36

A method for preventing angiogenesis comprising administering a composition comprising the polypeptide KIAA 1036 to vascular endothelial cells or expressing a polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 in said vascular endothelial cells.

### Claim 37 (depends on 36)

The method of claim 36, in which the composition is administered to a subject or said polynucleotide is expressed in a subject.

### Claim 38 (depends on 36)

The method of claim 36, in which the composition is administered to vascular endothelial cells in culture or said polynucleotide is expressed in cells in culture.

### Claim 39 (depends on 37)

The method of claim 37, in which the subject presents with colon cancer or ovarian cancer.
